Angela Hong1,2, Xiaoying Zhang3, Deanna Jones3, Mei Zhang1,2, C Soon Lee4, J Guy Lyons1, Anne-Sophie Veillard5, Barbara Rose3. 1. a Central Clinical School, Sydney Medical School, The University of Sydney , NSW , Australia. 2. b Department of Radiation Oncology , Lifehouse , NSW , Australia. 3. c Department of Infectious Diseases and Immunology , Sydney Medical School, The University of Sydney , NSW , Australia. 4. d Department of Anatomical Pathology , Royal Prince Alfred Hospital , Camperdown , NSW , Australia. 5. e NHMRC Clinical Trials Center, The University of Sydney , NSW , Australia.
Abstract
BACKGROUND: The study aimed to identify prognostic markers to improve the management of patients with HPV positive OSCC Methods: We determined the ratio of HPV E6*I and E6*II splice variants by quantitative RT-PCR in 177 HPV positive OSCC and correlated the findings with other clinicopathological data Results: There was no significant difference in locoregional recurrence (HR 1.72 p = 0.24) and death (HR 1.65, p = 0.13) among patients whose tumors had an E6*I/*II ratio ≥1 compared with an E6*I/*II ratio of <1. Univariate analysis showed that patients with E6*I/*II ≥1 OSCC were more likely to have an event. In the multivariable analysis, there was a trend for more events in patients with E6*I/*II ratio ≥1 (HR 1.70, 95% CI 0.95-3.03, p = 0.07) CONCLUSION: Our data suggest that the use of HPV 16 spliced transcripts may help to predict for poorer outcomes in patients with HPV positive OSCC.
BACKGROUND: The study aimed to identify prognostic markers to improve the management of patients with HPV positive OSCC Methods: We determined the ratio of HPV E6*I and E6*II splice variants by quantitative RT-PCR in 177 HPV positive OSCC and correlated the findings with other clinicopathological data Results: There was no significant difference in locoregional recurrence (HR 1.72 p = 0.24) and death (HR 1.65, p = 0.13) among patients whose tumors had an E6*I/*II ratio ≥1 compared with an E6*I/*II ratio of <1. Univariate analysis showed that patients with E6*I/*II ≥1 OSCC were more likely to have an event. In the multivariable analysis, there was a trend for more events in patients with E6*I/*II ratio ≥1 (HR 1.70, 95% CI 0.95-3.03, p = 0.07) CONCLUSION: Our data suggest that the use of HPV 16 spliced transcripts may help to predict for poorer outcomes in patients with HPV positive OSCC.
Entities:
Keywords:
E6; head and neck cancer; human papillomavirus; oropharyngeal cancer; p16
Authors: Paul M Weinberger; Ziwei Yu; Bruce G Haffty; Diane Kowalski; Malini Harigopal; Janet Brandsma; Clarence Sasaki; John Joe; Robert L Camp; David L Rimm; Amanda Psyrri Journal: J Clin Oncol Date: 2006-01-09 Impact factor: 44.544
Authors: Niklas Reimers; Hans U Kasper; Soenke J Weissenborn; Hartmut Stützer; Simon F Preuss; Thomas K Hoffmann; Ernst Jan M Speel; Hans P Dienes; Herbert J Pfister; Orlando Guntinas-Lichius; Jens P Klussmann Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396
Authors: Serge J Smeets; Albertus T Hesselink; Ernst-Jan M Speel; Annick Haesevoets; Peter J F Snijders; Michael Pawlita; Chris J L M Meijer; Boudewijn J M Braakhuis; C René Leemans; Ruud H Brakenhoff Journal: Int J Cancer Date: 2007-12-01 Impact factor: 7.396
Authors: Tingting Qin; Lada A Koneva; Yidan Liu; Yanxiao Zhang; Anna E Arthur; Katie R Zarins; Thomas E Carey; Douglas Chepeha; Gregory T Wolf; Laura S Rozek; Maureen A Sartor Journal: Head Neck Date: 2020-05-14 Impact factor: 3.147
Authors: Yanxiao Zhang; Lada A Koneva; Shama Virani; Anna E Arthur; Alisha Virani; Pelle B Hall; Charles D Warden; Thomas E Carey; Douglas B Chepeha; Mark E Prince; Jonathan B McHugh; Gregory T Wolf; Laura S Rozek; Maureen A Sartor Journal: Clin Cancer Res Date: 2016-04-18 Impact factor: 12.531